Association of Polygenic Risk for Psychiatric Disorders with Cardiometabolic DiseaseCenter for Precision Psychiatry, University of Oslo, Oslo, Norway.
Genetic Epidemiology, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Centre for Clinical Brain Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK; Centre for Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK; Department of Medical and Molecular Genetics, King's College London, London, UK.
A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA, USA; Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Center for Precision Psychiatry, University of Oslo, Oslo, Norway.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA.
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Center for Precision Psychiatry, University of Oslo, Oslo, Norway; K.G. Jebsen Centre for Neurodevelopmental Disorders, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Mental Health and Suicide, Norwegian Institute of Public Health, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Center for Precision Psychiatry, University of Oslo, Oslo, Norway.
Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2025 (English)Manuscript (preprint) (Other academic)
Abstract [en]
IMPORTANCE: Clinical diagnoses of psychiatric disorders are associated with cardiometabolic diseases (CMDs) such as type 2 diabetes and ischemic heart diseases. Studying how genetic liability for psychiatric disorders relate to CMD risk will offer novel insight into the relationship between psychiatric disorders and CMDs. OBJECTIVE: To evaluate the associations between psychiatric polygenic risk scores (PRSs) and clinically diagnosed CMDs while accounting for cross-disorder pleiotropy.
DESIGN SETTING AND PARTICIPANTS: This study computed PRSs for attention deficit-hyperactivity disorder (ADHD), major depressive disorder (MDD), anxiety disorder, post-traumatic stress disorder (PTSD), bipolar disorder, and schizophrenia. The analysis was conducted in three population-based Northern European cohorts: the Swedish Twin Registry (STR, N=17,378 genotyped samples), the Estonian Biobank (EstBB, N=208,383), and the Norwegian Mother, Father and Child Cohort Study (MoBa, N=129,398). Associations between psychiatric PRSs and clinical diagnoses of 10 major CMDs (including metabolic diseases such as hyperlipidemia, obesity, and type 2 diabetes, and cardiovascular diseases such as hypertensive disease, arteriosclerosis, ischemic heart disease, heart failure, thromboembolic disease, cerebrovascular disease, and arrhythmias) were estimated using models that mutually adjusted for all psychiatric PRSs. Supplementary analyses were performed by additionally controlling for self-reported body mass index (BMI). A discordant twin-pair analysis was conducted in the STR (N=70,619) to assess the association between self-reported lifetime MDD and subsequent CMD risk while adjusting for familial factors shared between monozygotic and dizygotic co-twins.
MAIN OUTCOMES AND MEASURES: Psychiatric PRSs were constructed based on both all available genetic risk variants and genome-wide significant risk variants from large-scale GWASs. Clinical diagnoses of psychiatric disorders and CMDs were ascertained through electronic health records (with primary care records used exclusively in the EstBB). Lifetime self-reported MDD in the STR was assessed via the Composite International Diagnostic Interview Short Form.
RESULTS: PRSs for ADHD and MDD were associated with increased risk of all CMDs. The ADHD PRS showed stronger associations with metabolic disease, whereas the MDD PRS showed stronger associations with cardiovascular diseases. PRSs for anxiety disorder, PTSD, and bipolar disorder showed only limited associations with CMDs, while increased levels of schizophrenia PRSs were associated with decreased risk of CMDs. These associations remained after adjustment for BMI. Finally, twins endorsing lifetime MDD were found to have an increased risk of subsequent CMD diagnoses compared to their unexposed co-twins.
CONCLUSIONS AND RELEVANCE: PRSs for ADHD and MDD showed robust associations with risk of CMDs and self-reported MDD was associated with subsequent CMD risk even after adjusting for familial factors shared between co-twins. These findings provide robust evidence for genetic overlap between ADHD and MDD with CMDs.
Place, publisher, year, edition, pages
2025. article id 2025.03.11.25323757
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:oru:diva-120394DOI: 10.1101/2025.03.11.25323757PubMedID: 40162248OAI: oai:DiVA.org:oru-120394DiVA, id: diva2:1949566
Note
medRxiv. Article id: 11:2025.03.11.25323757.
PMID: 40162248
2025-04-032025-04-032025-04-03Bibliographically approved